FHTX
Foghorn·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 3
Consensus Rating "Strong Buy"
Bearish Engulfing
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About FHTX
Foghorn Therapeutics Inc.
A developer of therapeutics for genetically determined dependencies within the chromatin regulatory system
500 Technology Square, Ste 700, Cambridge, Massachusetts 02139
--
Foghorn Therapeutics Inc., was founded in October 2015. The company pioneered the discovery and development of a class of drugs targeting genetic deterministic dependence within the chromatin regulatory system, an untapped therapeutic opportunity intervention. The company's proprietary gene flow control platform provides it with a comprehensive, mechanical understanding of how the various components of the chromatin regulatory system interact, enabling it to identify and validate potential drug targets within the system.
Company Financials
EPS
FHTX has released its 2025 Q3 earnings. EPS was reported at -0.25, versus the expected -0.3, beating expectations. The chart below visualizes how FHTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
FHTX has released its 2025 Q3 earnings report, with revenue of 8.15M, reflecting a YoY change of 4.42%, and net profit of -15.85M, showing a YoY change of 17.12%. The Sankey diagram below clearly presents FHTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
